Gilead Sciences (NASDAQ: GILD) opened its new 182,000-square-foot Research Center in Foster City, California, marking a key milestone in its broader capital expenditure strategy. The facility expands the company’s domestic infrastructure for oncology, inflammation, and research data science.

Strategic Infrastructure Expansion

The new center is one of three major projects under Gilead’s announced $32 billion investment commitment to the United States through 2030. This capital allocation aims to strengthen U.S. research, development, and manufacturing capabilities while supporting approximately 3,000 high-quality domestic jobs.

Gilead currently employs approximately 11,000 people across the United States. More than 7,400 of these employees are based in California, with nearly 4,700 located in the Bay Area. The new Research Center will support approximately 325 employees, including 260 laboratory scientists.

Facility Details and Future Projects

The five-story facility features flexible laboratory neighborhoods and shared technology platforms designed to co-locate key research disciplines. It includes all-electric systems and energy-efficient design intended to support LEED Gold certification.

Two additional projects form part of this investment cluster:

What the Numbers Show

The concentration of Gilead’s workforce in California is significant. With more than 7,400 of its 11,000 U.S. employees based in the state, California accounts for approximately 67% of the company’s domestic headcount. The new facility reinforces this geographic dependency by adding specialized infrastructure for data science and oncology within the existing Bay Area cluster.

Daniel O’Day, Chairman and CEO, stated that the center reflects a long-term commitment to American innovation. Flavius Martin, MD, Executive Vice President of Research, noted that co-locating disciplines aims to accelerate discovery.

The U.S. Food and Drug Administration approved Gilead Sciences (NASDAQ: GILD) Bixlenvo on Thursday for treating HIV in virologically suppressed adults. The approval introduces the smallest once-daily single tablet regimen available.

Bixlenvo combines 75 mg of bictegravir and 50 mg of lenacapavir. It serves as the first and only single-tablet option for patients managing complex regimens who cannot use other available single-tablet therapies due to antiretroviral resistance or treatment complexity.

Clinical Trial Data

The FDA decision relied on Phase 3 results from the ARTISTRY-1 and ARTISTRY-2 trials. Data was presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026). Both trials evaluated Bixlenvo in adults who switched from complex multi-tablet regimens or from Biktarvy.

In both trials, Bixlenvo demonstrated comparable efficacy in maintaining virologic suppression at Week 48. The drug was generally well tolerated with no significant or new safety concerns identified.

Patient Profile and Safety

ARTISTRY-1 enrolled the oldest study population in a Phase 3 registrational trial for HIV-1 treatment to date. Participants had a median treatment duration of 28 years. Approximately 67% had NRTI resistance, and 81% were on complex regimens due to antiretroviral resistance. At trial start, participants took between two and 11 pills daily.

The most common adverse reactions reported in at least 2% of participants across the ARTISTRY program were headache (4%), nausea (3%), and diarrhea (2%). Switching to Bixlenvo was associated with improvements in certain fasting lipid parameters and participant-reported treatment satisfaction in ARTISTRY-1.

What the Numbers Show

The clinical data highlights a significant shift toward simplifying care for experienced patients. With 81% of ARTISTRY-1 participants on complex regimens due to resistance, the successful switch to a single tablet regimen demonstrates efficacy in a high-resistance population (67% NRTI resistance). This suggests Bixlenvo addresses a specific gap for patients who cannot tolerate standard STRs.

Dosage and Administration

Bixlenvo requires a two-day initiation dose with Sunlenca (lenacapavir). Thereafter, only Bixlenvo is taken orally once a day. The combination is not approved by any regulatory authority outside the United States.

Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, stated that Bixlenvo continues the company’s commitment to innovation in HIV. He noted that the pipeline includes potential daily, weekly, and longer-acting options.

Gilead Sciences shares were up 0.49% at $146.40 at the time of publication on Monday.